The Cost Effectiveness of Newer Epilepsy Treatments
Author
Abstract
Suggested Citation
DOI: 10.2165/11597110-000000000-00000
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Jasmina Ivanova & Howard Birnbaum & Yohanne Kidolezi & Ying Qiu & David Mallett & Sue Caleo, 2010. "Economic Burden of Epilepsy among the Privately Insured in the US," PharmacoEconomics, Springer, vol. 28(8), pages 675-685, August.
- David Meltzer, 1997. "Accounting for Future Costs in Medical Cost-Effectiveness Analysis," NBER Working Papers 5946, National Bureau of Economic Research, Inc.
- John A. Nyman, 2006. "More on survival consumption costs in cost‐utility analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 319-322, March.
- Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.
- Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
- Á Benedict & L Verdian & G Maclaine, 2011. "Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK," PharmacoEconomics, Springer, vol. 29(12), pages 1014-1014, December.
- Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
- Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
- Ágnes Benedict & Lara Verdian & Grant Maclaine, 2010. "The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK," PharmacoEconomics, Springer, vol. 28(3), pages 185-199, March.
- repec:dau:papers:123456789/12303 is not listed on IDEAS
- Pierre Lévy, 2002. "Economic Evaluation of Antiepileptic Drug Therapy: A Methodologic Review," Post-Print hal-01293849, HAL.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Bengt Liljas, 2011. "Welfare, QALYs, and costs – a comment," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 68-72, January.
- Douglas Lundin & Joakim Ramsberg, 2008. "On survival consumption costs – a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 293-297, February.
- Megan Perry-Duxbury & James Lomas & Miqdad Asaria & Pieter Baal, 2022.
"The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS,"
PharmacoEconomics, Springer, vol. 40(2), pages 233-239, February.
- Perry-duxbury, Megan & Lomas, James & Asaria, Miqdad & Van Baal, Pieter, 2022. "The relevance of including future healthcare costs in cost-effectiveness threshold calculations for the UK NHS," LSE Research Online Documents on Economics 112503, London School of Economics and Political Science, LSE Library.
- Bengt Liljas & Göran S. Karlsson & Nils‐Olov Stålhammar, 2008. "On future non‐medical costs in economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 17(5), pages 579-591, May.
- Magnus Johannesson;Bengt Jonsson;Linus Jonsson;Gisela Kobelt;Niklas Zethraeus, 2009. "Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?," Briefing 000228, Office of Health Economics.
- Kristian Bolin, 2012. "Economic Evaluation of Smoking-Cessation Therapies," PharmacoEconomics, Springer, vol. 30(7), pages 551-564, July.
- Erik Nord & Christoffer Lamøy, 2018. "Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary," PharmacoEconomics - Open, Springer, vol. 2(4), pages 357-358, December.
- John A. Nyman, 2011. "Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 56-67, January.
- Bengt Liljas, 2010. "On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 5-13, February.
- Richardson, Jeff & McKie, John, 2007. "Economic evaluation of services for a National Health Scheme: The case for a fairness-based framework," Journal of Health Economics, Elsevier, vol. 26(4), pages 785-799, July.
- Vincent T Janmaat & Marco J Bruno & Suzanne Polinder & Sylvie Lorenzen & Florian Lordick & Maikel P Peppelenbosch & Manon C W Spaander, 2016. "Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-10, April.
- John A. Nyman, 2006. "More on survival consumption costs in cost‐utility analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 319-322, March.
- Kenneth Manton & Kenneth Land, 2000. "Active life expectancy estimates for the U.S. elderly population: A multidimensional continuous-mixture model of functional change applied to completed Cohorts, 1982–1996," Demography, Springer;Population Association of America (PAA), vol. 37(3), pages 253-265, August.
- Stefan Felder, 2006. "Lebenserwartung, medizinischer Fortschritt und Gesundheitsausgaben: Theorie und Empirie," Perspektiven der Wirtschaftspolitik, Verein für Socialpolitik, vol. 7(s1), pages 49-73, May.
- Ernst R. Berndt & David M. Cutler & Richard Frank & Zvi Griliches & Joseph P. Newhouse & Jack E. Triplett, 2001.
"Price Indexes for Medical Care Goods and Services -- An Overview of Measurement Issues,"
NBER Chapters, in: Medical Care Output and Productivity, pages 141-200,
National Bureau of Economic Research, Inc.
- Ernst R. Berndt & David M. Cutler & Richard G. Frank & Zvi Griliches & Joseph P. Newhouse, 1998. "Price Indexes for Medical Care Goods and Services: An Overview of Measurement Issues," NBER Working Papers 6817, National Bureau of Economic Research, Inc.
- Ernst R. Berndt & David M. Cutler & Richard G. Frank & Zvi Griliches & Joseph P. Newhouse & Jack E. Triplett, 1998. "Price Indexes for Medical Care Goods and Services: An Overview of Measurement Issues," Harvard Institute of Economic Research Working Papers 1851, Harvard - Institute of Economic Research.
- Pieter H. M. van Baal & Talitha L. Feenstra & Johan J. Polder & Rudolf T. Hoogenveen & Werner B. F. Brouwer, 2011.
"Economic evaluation and the postponement of health care costs,"
Health Economics, John Wiley & Sons, Ltd., vol. 20(4), pages 432-445, April.
- van Baal, P.H. & Feenstra, T.L. & Polder, J.J. & Hoogenveen, R.T. & Brouwer, W., 2011. "Economic evaluation and the postponement of health care costs," Other publications TiSEM ee3d1a20-234a-46d7-8acd-d, Tilburg University, School of Economics and Management.
- Kenkel, Don, 1997. "On valuing morbidity, cost-effectiveness analysis, and being rude," Journal of Health Economics, Elsevier, vol. 16(6), pages 749-757, December.
- Michael E. Darden & Robert Kaestner, 2022.
"Smoking, selection, and medical care expenditures,"
Journal of Risk and Uncertainty, Springer, vol. 64(3), pages 251-285, June.
- Michael E. Darden & Robert Kaestner, 2022. "Smoking, Selection, and Medical Care Expenditures," NBER Working Papers 29885, National Bureau of Economic Research, Inc.
- David M. Cutler & Ellen Meara, 1998.
"The Medical Costs of the Young and Old: A Forty-Year Perspective,"
NBER Chapters, in: Frontiers in the Economics of Aging, pages 215-246,
National Bureau of Economic Research, Inc.
- David M. Cutler & Ellen Meara, 1997. "The Medical Costs of The Young and Old: A Forty Year Perspective," NBER Working Papers 6114, National Bureau of Economic Research, Inc.
- Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:30:y:2012:i:10:p:903-923. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.